Education
About Us
Working with TipRanks
Follow Us
Immutep (IMMP)
NASDAQ:IMMP
IMMP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.32 - $2.72
Previous CloseN/A
Volume50.42K
Average Volume (3M)78.03K
Market Cap
$235.12M
Enterprise Value$155.08M
Total Cash (Recent Filing)$159.26M
Total Debt (Recent Filing)$1.68M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Feb 19, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding146,786,480
10 Day Avg. Volume81,203
30 Day Avg. Volume78,033
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue31.79
Enterprise Value/Gross Profit-3.73
Enterprise Value/Ebitda-3.18
Forecast
1Y Price Target
$12.00Price Target Upside636.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe P2b TACTI-003 trial showed 17.6-month median overall survival for the combination, comparing favorably to historical benchmarks.
Funding And Financial StabilityThe company has a strong cash position, expecting to be funded through the end of 2026.
Regulatory FeedbackImmutep received positive feedback from the FDA regarding future late-stage development of eftilagimod alpha (efti) + Keytruda for metastatic head & neck cancer.
Bears Say
Competitive MarketIf the INSIGHT-003 data holds up in the larger TACTI-004 study, the probability of approval in 1L favoring Immutep is expected to increase, as this could become the preferred treatment.
Development RisksImmutep has requested a meeting with the FDA to discuss the path forward, indicating progress in regulatory engagement.
Regulatory UncertaintyUnder FDA’s Project FrontRunner, two potential paths forward for efti include either a randomized registrational trial or a smaller single-arm study, which could potentially support accelerated approval.
Immutep News
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $1.32 and its highest was $2.72 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is $235.12M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Feb 19, 2026 which is in 168 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Aug 27, 2025. The company reported -$0.177 earnings per share for the quarter, beating the consensus estimate of -$0.186 by $0.009.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -0.16.
How many shares outstanding does Immutep have?
Immutep has 146,786,480 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -$0.177 in its last earnings report, beating expectations of -$0.186. Following the earnings report the stock price went down -1.775%.
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in IMMP
Immutep Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (636.20% Upside)
$12.00 (636.20% Upside)
Blogger Sentiment
Bullish
IMMP Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 564.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 12.7%
Last 30 Days ▲ 12.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.57%
12-Months-Change
Fundamentals
Return on Equity
-35.86%
Trailing 12-Months
Asset Growth
-23.58%
Trailing 12-Months
Company Description
Immutep
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
IMMP Stock 12 Month Forecast
Average Price Target
$12.00
▲(636.20% Upside)
Technical Analysis
Astria Therapeutics
―
Y-Mabs Therapeutics
―
iTeos Therapeutics
―
Atea Pharmaceuticals
―
Compass Therapeutics
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.39% Other Institutional Investors
99.19% Public Companies and
Individual Investors